Following the strange year for the biopharma industry that was 2024, insiders and analysts alike are waiting expectantly to see how trends in layoffs, drug shortages, clinical trials and more play out in 2025. Meanwhile, a second Trump term and a spree of related health agency nominations raise serious questions about how health policy could shift over the next 12 months and beyond.

In this week’s episode of “The Top Line,” we explore the trends that defined the industry in 2024 and tackle predictions about how 2025 could shake out for biopharmas big and small. Fierce Pharma’s Fraiser Kansteiner and Fierce Biotech’s Gabrielle Masson discuss 2024’s layoff count, the state of GLP-1 supplies, the future of clinical trial research, potential policy shakeups and more.

To learn more about the topics in this episode:

• Analysts predict M&A, IPO uptick in 2025 but don't expect 'floodgates to suddenly open'

• Big Pharma layoff rounds jump 281% in '24, but overall industry rates similar to '23

• 2025 forecast: After Novo, Lilly expansion sprees, 'positive signals' emerge around future supply of GLP-1 drugs

• From AI and layoffs to supply chains and political unknowns, Deloitte outlines key areas for biopharma to watch in 2025 

This episode is brought to you by Cencora. Learn more at cencora.com/breakthrough.